认知储备可以抵消与APOE相关的阿尔茨海默氏症风险吗? 一个系统的审查
Sayonara Pereira da Silva1, Charikleia Lampraki2, Tainá Dos Santos Rêgo3
1Department of Psychology, University of Geneva, Geneva, Switzerland; Center for the Interdisciplinary Study of Gerontology and Vulnerability, University of Geneva, Geneva, Switzerland; Lemanic Neuroscience Doctoral School, Geneva and Lausanne, Switzerland; Swiss Centre of Expertise in Life Course Research LIVES, Lausanne and Geneva, Switzerland.
Ageing research reviews
|June 24, 2025
概括
认知储备 (CR) 可能会影响阿尔茨海默氏症 (AD) 风险,即使有像APOE变种这样的遗传倾向. 终身经验与遗传因素相互作用,以复杂的方式影响AD的结果.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经认知障碍,其特点是记忆丧失和执行功能障碍.
- 遗传因素,如APOE基因变异,影响AD易感性.
- 通过教育和复杂职业等终身经验建立的认知储备 (CR) 可能会调节AD风险.
研究的目的:
- 系统地审查和分析研究APOE相关的AD结果和CR之间的相互作用.
- 了解CR如何影响遗传倾向对阿尔茨海默病的影响.
主要方法:
- 在PubMed和Web of Science数据库中进行了全面的文献搜索.
- 选了33,861个参考文献,其中15项研究符合分析的纳入标准.
- 研究分析基于研究设计,人口特征,CR代理和测量结果.
主要成果:
- 审查的研究提出了关于APOE和CR之间的相互作用的混合结果.
- 七项研究表明CR的保护作用,四项显示有害作用,四项没有发现显著的相互作用.
- 发现的变化可能源于使用单个CR代理程序,可能只捕捉CR的有限方面.
结论:
- CR可能与遗传风险因素相互作用,可能影响阿尔茨海默病的易感性.
- 包括遗传和CR在内的个体风险因素之间的复杂相互作用需要进一步调查.
- 这些发现对老龄化研究,CR研究和与阿尔茨海默病预防有关的公共卫生政策有影响.
相关概念视频
01:26Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265